Molecule Name |
DB11575
|
DrugBank Groups |
Approved
|
Cluster No |
1165
|
Smiles |
S(=O)(=O)(N=C(O)C6(N=C(O)C1(N2(C(=O)C(N=C(OC5(C(CCCCCC=4(C(OC(C1)C2)=NC=3(C(=CC=C(C=3)OC)N=4)))C5))O)C(C)(C)C)))(C(C=C)C6))C7(CC7)
|
Download |
mol2, pdbqt
|
TPSA |
214,07
|
Non-H Atoms |
54
|
Non-C/H Atoms |
16
|
Metal-Atoms |
0
|
Electronegative Atoms |
16
|
Stereo Centers |
7
|
Rotatable Bonds |
7
|
Rings Closures |
7
|
Small Rings |
6
|
Aromatic Rings |
2
|
Aromatic Atoms |
10
|
sp3-Atoms |
31
|
Symmetric atoms |
4
|
cLogS |
-7,376
|
MW |
766,914
|
cLogP |
4,8528
|
HBA |
15
|
HBD |
3
|
Ro5 violations |
2
|
Druglikeness |
-8,0585
|
DrugScore |
6,49895702058089E-02
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
high
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,6621
|
Caco-2 Permeability 2 |
0,6597
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
1,2439
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,582
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,67
|
Carcinogenicity (Three-class) |
Non-required
|